At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
omega-3 fatty acid +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma
In Brief
A Phase 2 clinical trial evaluating omega-3 fatty acid, placebo, and 1 other intervention for Ductal Breast Carcinoma in Situ and 8 related conditions. Completed, enrolled 57 participants across 1 site.
Detailed Summary
This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3 fatty acid may help doctors learn more about the effects of omega-3 fatty acid on tumor cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuctal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartNov 2013
Primary CompletionJul 2018
TodayJul 2026
First PostedJun 5, 2013
Enrollment StartNov 1, 2013
Primary CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 13.1 years ago
Interventions
omega-3 fatty aciddrug
Given PO
placeboother
Given PO
laboratory biomarker analysisother
Correlative studies